Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Signs License For Regeneron’s VelocImmune To Bolster Antibody Platform

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal, valued at potentially $120 million, is Regeneron’s second for the human monoclonal antibody discovery technology.

You may also be interested in...



Sanofi Strengthens Monoclonal Antibody Access With $560 Million Regeneron Deal

One of the first candidates targeted for development will be an interleukin-6 receptor, a potential competitor to TNF inhibitors, for RA.

Sanofi Strengthens Monoclonal Antibody Access With $560 Million Regeneron Deal

One of the first candidates targeted for development will be an interleukin-6 receptor, a potential competitor to TNF inhibitors, for RA.

Astellas Advances Antibody R&D Agenda With Agensys Purchase Worth Up To $537 Million

Privately held Agensys brings a proprietary portfolio of cancer targets, a preclinical pipeline of mAbs and small proteins, and antibody manufacturing capabilities.

Related Content

Topics

UsernamePublicRestriction

Register

PS065835

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel